Lamine F, Eutamène H, Fioramonti J, Buéno L, Théodorou V
INRA, Toulouse, France.
Scand J Gastroenterol. 2004 Dec;39(12):1250-8. doi: 10.1080/00365520410007953.
It has recently been shown that Lactobacillus farciminis treatment exerts an anti-inflammatory effect in trinitrobenzene sulphonic acid (TNBS)-induced colitis partly through a nitric oxide release by this strain. The aim of this study was to evaluate whether L. farciminis treatment shares also the general mechanisms of action involved in the beneficial effect of probiotics in the colonic inflammatory process.
Rats received L. farciminis for 15 days before and 4 days after intracolonic administration of TNBS or vehicle. The following parameters were evaluated: macroscopic damage of colonic mucosa, myeloperoxidase activity, cytokine mucosal levels, bacterial profile in colonic content and mucosa, bacterial translocation and colonic paracellular permeability.
In the absence of TNBS, L. farciminis treatment reduced colonic paracellular permeability and increased the IL-10 level in the colonic wall. TNBS administration induced colonic macroscopic damage, associated with an increase of myeloperoxidase activity, bacterial translocation, colonic paracellular permeability and IL-1beta mucosal level, and a decrease in IL-10 mucosal level. Moreover, the bacterial profile of colonic content and mucosa was modified. All these alterations were abolished or significantly reduced by L. farciminis treatment.
As previously shown, L. farciminis treatment improves TNBS-induced colitis. This study indicates that, in addition to the nitric oxide released by this bacterial strain, the anti-inflammatory action of L. farciminis involves also normalization of colonic microflora, prevention of bacterial translocation, enhancement of barrier integrity and a decrease in the IL-1beta mucosal level.
最近的研究表明，发酵乳杆菌治疗可部分通过该菌株释放一氧化氮，对三硝基苯磺酸（TNBS）诱导的结肠炎发挥抗炎作用。本研究的目的是评估发酵乳杆菌治疗是否也具有益生菌在结肠炎症过程中有益作用所涉及的一般作用机制。
大鼠在结肠内注射TNBS或赋形剂前15天及注射后4天接受发酵乳杆菌治疗。评估以下参数：结肠黏膜的宏观损伤、髓过氧化物酶活性、细胞因子黏膜水平、结肠内容物和黏膜中的细菌谱、细菌易位和结肠旁细胞通透性。
在未注射TNBS的情况下，发酵乳杆菌治疗降低了结肠旁细胞通透性，并提高了结肠壁中的IL-10水平。注射TNBS导致结肠宏观损伤，伴有髓过氧化物酶活性增加、细菌易位、结肠旁细胞通透性和IL-1β黏膜水平升高，以及IL-10黏膜水平降低。此外，结肠内容物和黏膜的细菌谱发生了改变。发酵乳杆菌治疗消除了所有这些改变或使其显著减轻。
如先前所示，发酵乳杆菌治疗可改善TNBS诱导的结肠炎。本研究表明，除了该菌株释放的一氧化氮外，发酵乳杆菌的抗炎作用还涉及结肠微生物群的正常化、细菌易位的预防、屏障完整性的增强以及IL-1β黏膜水平的降低。
